Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

Clinical trial NCT05363631 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05363631
Sponsor: Mohammed Milhem
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma Metastatic

Start date: 2022-09-19
Primary completion: 2026-12-31
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.